Thus, studies have shown that amino acid depletion activates GCN2 in ALL cell lines and inhibition of the enzyme sensitizes both ALL and AML cell lines to treatment with L-asparaginase [32], a first-line therapy for ALL and prospective therapy for AML [33]. Here, EIF2AK4 is linked to acute myeloid leukemia.